Clinical trials: psoriasis
Plaque Psoriasis
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults
This trial will be a double-blind, single-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18…
- Trial name
- NCT02993328
- Testing
- SAN021 Serum
- Where
- Australia
- Sponsor
- Santalis Pharmaceuticals, Inc.
Psoriasis Vulgaris
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
The purpose is to compare the efficacy of treatment with LEO 90100 at Week 4 to that of calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis vulgaris
- Trial name
- NCT02132936
- Testing
- LEO 90100 aerosol foam, Aerosol foam vehicle, Calcipotriol BDP gel
- Where
- France
- Volunteers
- 504 people
- Sponsor
- LEO Pharma
Inflammation, Psoriasis
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
This trial is conducted in the United States of America (USA). The aim of this clinical trial is evaluate the safety and tolerability of anti-IL-20 in patients with psoriasis and to determine the preliminary efficacy in an…
- Trial name
- NCT01261767
- Testing
- anti-IL-20
- Where
- 16 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novo Nordisk A/S
Nail Psoriasis, Plaque Psoriasis
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.
- Trial name
- NCT00581100
- Testing
- etanercept
- Volunteers
- 136 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Healthy Subjects
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions.
- Trial name
- NCT02534636
- Testing
- BMS-986165, Interferon alpha-2a recombinant, Famotidine
- Where
- Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation…
- Trial name
- IMMagine (NCT05959070)
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis.
- Trial name
- NCT02514694
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriatic Plaque
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis
This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114…
- Trial name
- NCT03630939
- Testing
- ESR-114
- Where
- 10 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Escalier Biosciences B.V.
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA).
- Trial name
- VELOTA (NCT07321873)
- Testing
- JNJ-88545223
- Where
- 75 sites in United States, China and 6 more
- Volunteers
- 157 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.
- Trial name
- NCT00975637
- Testing
- 70 mg SC, 210 mg SC, 140 mg SC
- Volunteers
- 198 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
This is a phase Ⅲ, randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the efficacy, safety, tolerability, and immunogenicity of subcutaneous Tildrakizumab in subjects with moderate to…
- Trial name
- NCT05108766
- Testing
- Tildrakizumab 100 mg
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
- Trial name
- NCT02932878
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
- Trial name
- STAR (NCT04929210)
- Testing
- Guselkumab
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 411 people
- Sponsor
- Janssen Research & Development, LLC
Mild-to-moderate Psoriasis Vulgaris
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
- Trial name
- 2011-00500-15 (NCT01595997)
- Testing
- DLX105
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Delenex Therapeutics AG
Psoriasis
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study.
- Trial name
- POETYK PSO-LTE (NCT04036435)
- Testing
- BMS-986165
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,466 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of multiple-dose HSK47388 versus placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07158268
- Testing
- HSK47388
- Volunteers
- 220 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.